James K. Fong - Jan 24, 2023 Form 4 Insider Report for CTI BIOPHARMA CORP (CTIC)

Role
EVP & Chief Commercial Officer
Signature
Jim Fong
Stock symbol
CTIC
Transactions as of
Jan 24, 2023
Transactions value $
-$505,110
Form type
4
Date filed
1/26/2023, 03:49 PM
Previous filing
Mar 11, 2022
Next filing
Mar 16, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTIC common stock Options Exercise $94.9K +100K +2805.05% $0.95* 104K Jan 24, 2023 Direct
transaction CTIC common stock Sale -$600K -100K -96.56% $6.00 3.57K Jan 24, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTIC Non-Qualified Stock Option (right to buy) Award $0 +288K $0.00 288K Feb 19, 2019 Common Stock 288K $0.95 Direct F2
transaction CTIC Non-Qualified Stock Option (right to buy) Options Exercise $0 -100K -34.72% $0.00 188K Jan 24, 2023 Common Stock 100K $0.95 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person.
F2 One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022.